Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Vaxcyte, Inc.NASDAQ: PCVX

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$289.55M, compared with -$161.58M a year earlier. Trailing-twelve-month EBITDA was -$1.05B.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -65.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$289.55M+8.0% QoQ
Last fiscal yearDec 2025
-$741.77M-65.5% YoY
LTMJun 2026
-$1.05B-116.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-79.2%+100.0%+179.2 pp
1 year-65.5%+100.0%+165.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(741.77M) USD
Year-over-year change
-65.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -116.2% is the 7th highest of 9, against a peer median of -18.4%.
PCVX Competitors
EBITDA for PCVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
NVAXNovavax, Inc.LTM Mar 2026-$42.13M USD-107.6%—7.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.01B USD-332.3%—550.8%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.05B USD-116.2%——
MRNAModerna, Inc.LTM Sep 2026-$2.46B USD+16.4%—97.2%
Peer median (excluding PCVX) —-18.4%-9.6%77.4%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development78.41M169.45M332.34M476.64M794.31M
Selling, General & Admin25.26M39.81M60.7M92.9M129.37M
Operating Expenses103.67M232.26M468.04M569.55M923.68M
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
EBITDA(96.61M)(214.03M)(392.1M)(448.08M)(741.77M)
EBITDA Margin—————
Operating Income(103.67M)(232.26M)(468.04M)(569.55M)(923.68M)
Operating Margin—————
Interest Income344K8.36M62.91M109.99M119.72M
Interest Expense7K2K000
Other Income / Expenses3.59M8.77M65.78M105.62M157.05M
Income Before Tax(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Net Margin—————
EPS (Basic)(1.93)(3.44)(4.14)(3.80)(5.63)
EPS (Diluted)(1.93)(3.44)(4.14)(3.80)(5.63)
Weighted Avg Shares51.92M64.88M97.16M122M136.09M
Weighted Avg Shares (Diluted)51.92M64.88M97.16M122M136.09M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.